Injectable Self-Healing Hydrogel with LL-37 Derivative Treats Infected Skin Wounds
Background
Infected skin wounds, particularly those caused by antibiotic-resistant bacteria, pose a significant global health challenge, leading to prolonged hospital stays and increased mortality. Traditional treatments often struggle with effective drug delivery and sustained antimicrobial action, contributing to treatment failures and the rise of superbugs. There is an urgent need for innovative strategies that can provide both potent antimicrobial effects and promote tissue regeneration. This study addresses the knowledge gap in developing a localized, sustained, and effective delivery system for antimicrobial peptides to treat complex infected wounds.
Results
The novel hydrogel-LL-37 derivative combination demonstrated superior therapeutic efficacy compared to control groups. Treated wounds showed significantly accelerated closure, achieving 92% wound closure by day 14, whereas the hydrogel-only group reached only 55% closure and the saline control 30%. Bacterial load in the infected wounds treated with the hydrogel-LL-37 derivative was reduced by 3-log units (99.9% reduction) within 72 hours, a significantly greater reduction than the 1-log unit reduction observed in the free LL-37 solution group. Furthermore, histological analysis revealed a 2.5-fold increase in collagen deposition and a 3-fold increase in angiogenesis (new blood vessel formation) in the treated wounds, indicating enhanced tissue regeneration. Inflammatory markers, such as IL-6 and TNF-α, were also significantly suppressed by 70% compared to untreated controls, highlighting the anti-inflammatory benefits.
Why It Matters
This research presents a highly promising strategy for treating difficult-to-manage infected skin wounds, particularly those resistant to conventional antibiotics. The injectable, self-healing nature of the hydrogel ensures sustained release of the antimicrobial peptide, overcoming limitations of short peptide half-life and frequent dosing. This approach could significantly improve patient outcomes by accelerating wound healing, reducing bacterial burden, and mitigating inflammation. The findings suggest a clear path towards developing a novel clinical therapeutic for chronic wounds, burns, and surgical site infections. Future steps include evaluating its efficacy in larger animal models, assessing long-term safety, and eventually progressing to human clinical trials (Phase I/II).